Iterum Therapeutics plc (ITRMF) Net Cash Flow (2017 - 2025)

Iterum Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at -$2.0 million in Q3 2025.

• On a quarterly basis, Net Cash Flow fell 123.97% year-over-year to -$2.0 million in Q3 2025; TTM through Sep 2025 was -$2.4 million, a 127.51% decrease from a year earlier, with the FY2024 full-year figure at $18.1 million, up 221.18% from the prior year.
• Net Cash Flow was -$2.0 million for Q3 2025 at Iterum Therapeutics, down from $369000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $51.9 million in Q1 2021, with the low at -$30.1 million in Q2 2021.
• Average Net Cash Flow over 5 years is -$188578.9, with a median of -$1.2 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 744.84% in 2024, then slumped 951.3% in 2025.
• Over 5 years, Net Cash Flow stood at -$8.6 million in 2021, then soared by 106.38% to $546000.0 in 2022, then soared by 132.42% to $1.3 million in 2023, then jumped by 744.84% to $10.7 million in 2024, then sank by 118.91% to -$2.0 million in 2025.
• The last three Net Cash Flow figures came in at -$2.0 million (Q3 2025), $369000.0 (Q2 2025), and -$11.4 million (Q1 2025), per Business Quant data.